Wednesday, May 27, 2015

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical seeking CE Mark for TULSA-PRO this year

May 26, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac&feature=youtu.be’]

Tweet Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of prostrate cancer will be sufficient to file for CE Mark approval in Europe before the end of 2015. “We hope to launch TULSA-PRO in […]

Provectus taking novel path to treat cancer

Provectus taking novel path to treat cancer

May 19, 2015 by · Leave a Comment 

Tweet Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose Bengal, a first-in-class halogenated xanthene. “We are taking a different type of molecule and a different basis for the mechanism of action than has been used […]

T2 Biosystems to double sales force this year

T2 Biosystems to double sales force this year

May 12, 2015 by · Leave a Comment 

Tweet T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx instrument for the detection of Candida fungal infections that cause sepsis. “Our focus is on closing 30 accounts this year within […]

Axcelon leverages bacterial cellulose expertise with Nanoderm launch

Axcelon leverages bacterial cellulose expertise with Nanoderm launch

May 5, 2015 by · Leave a Comment 

Tweet Axcelon Biopolymers, which plans to go public in the current quarter, has developed a sales and marketing plan with a leading wholesaler and its own sales team to gain maximum market share in Canada for its Nanoderm bacterial cellulose dressing to heal burns and wounds. “We also have ongoing discussions with local distributors in […]

TransEnterix readying FDA filing of SurgiBot in mid-year

TransEnterix readying FDA filing of SurgiBot in mid-year

April 28, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=L6Bbk1MvHN0′]

Tweet TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate a six-to-nine month review cycle for our 510(k) submission and hope to launch in the first half of 2016,” CEO, Todd Pope, says in an […]

In conversation with Dr. Shai Yarkoni

In conversation with Dr. Shai Yarkoni

April 21, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=VRkLBen0HaE’]

Tweet As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start-ups in the life-sciences field, and serves on the board of noted institutes in Israel and the world. Prior to founding Cellect, […]

In conversation with Greg Trudel

In conversation with Greg Trudel

April 14, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=7TkiF1ODwWg’]

Tweet As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with ConMed Electrosurgery, SilverGlide Surgical Technologies, and Stryker. Most recently, he was global director of marketing for a division within the Surgical Solutions […]

Relmada championing four pain drug candidates

Relmada championing four pain drug candidates

April 7, 2015 by · Leave a Comment 

Tweet Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. “It is very unusual for a startup or even a mid-sized biotech company to have four different medications in clinical development for pain relief,” Dr. Eliseo Salinas, president […]

In conversation with Dr. Isaac Ciechanover

In conversation with Dr. Isaac Ciechanover

March 31, 2015 by · Leave a Comment 

Tweet As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He was a former partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent a decade as Celgene’s executive […]

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). The company also has a second drug candidate, Actimab-A, now in a […]

Next Page »

Email Newsletters with Constant Contact
Google+